Located in Shangdong Mingshui Development Zone in China, its production site offers Recombinant Human Erythropoietin Injection(EPO)£ Recombinant Human Granulocyte Colony-stimulating Factor Injection(rh-G-CSF)Filgrastim£ and Combined Clostridium Butyricum and Bifidobacterium Powders, Live for clinical and commercial use. Its workshop for genetically engineered drugs has area of 1, 500 square meters, and workshop for micro-ecological drugs covers 2, 000 square meters. Both workshops have passed China s GMP certification. The company plans to construct new factory buildings to improve production capacity and meet increasing market demands.The company develops recombinant genetic biological drugs and micro-ecological preparation, to serve the clinical treatment needs of kidney diseases, tumor, and gastrointestinal diseases. It has become a leading player in China s biopharmaceutical industry after more than 10 years of development.